Home › Funds › WT Wealth Management › PPH
WT Wealth Management position in PPH
VANECK PHARMACEUTICAL ETF
WT Wealth Management reported holding 47,796 shares of PPH (VANECK PHARMACEUTICAL ETF) in its Q3 2026 13F filing — a position valued at US$5.2M, representing 1.46% of its reported portfolio and ranking #18 among its reported holdings. WT Wealth Management has disclosed PPH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR
How WT Wealth Management's PPH position evolved
WT Wealth Management first disclosed a stake in PPH in Q3 2023 at 35,458 shares (US$2.8M). The position peaked in Q2 2026 at 53,786 shares, worth US$5.9M. Across 13 filings, WT Wealth Management increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 47,796 shares valued at US$5.2M — a reduction of -5,990 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 35.46K | $2.83M | New |
| Q4 2023 | 39.61K | $3.22M | Add |
| Q1 2024 | 40.76K | $3.70M | Add |
| Q2 2024 | 50.24K | $4.60M | Add |
| Q3 2024 | 53.66K | $5.08M | Add |
| Q4 2024 | 56.69K | $4.89M | Add |
| Q1 2025 | 51.69K | $4.71M | Reduce |
| Q2 2025 | 46.60K | $4.10M | Reduce |
| Q3 2025 | 45.63K | $4.12M | Reduce |
| Q4 2025 | 42.13K | $4.35M | Reduce |
| Q1 2026 | 50.38K | $5.23M | Add |
| Q2 2026 | 53.79K | $5.88M | Add |
| Q3 2026 | 47.80K | $5.23M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PPH and 13F data
PPH (VANECK PHARMACEUTICAL ETF) is a company whose sector is not yet classified in our data. 20 other funds we track also report a position in PPH — the largest reported positions include J.Safra Asset Management Corp (US$35.0M), Avalon Trust Co (US$28.8M), ADAMSBROWN WEALTH CONSULTANTS LLC (US$16.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PPH
- J.Safra Asset Management Corp 319.64K sh · $34.95M · Q2 2026
- Avalon Trust Co 263.83K sh · $28.85M · Q2 2026
- ADAMSBROWN WEALTH CONSULTANTS LLC 154.11K sh · $16.85M · Q2 2026
- Rye Brook Capital LLC 70.25K sh · $7.69M · Q3 2026
- Fluent Financial, LLC 26.90K sh · $2.94M · Q3 2026
More on WT Wealth Management
FAQ
How long has WT Wealth Management held PPH?
WT Wealth Management has disclosed PPH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is WT Wealth Management's current position in PPH?
As of Q3 2026, WT Wealth Management holds 47.80K shares of PPH (VANECK PHARMACEUTICAL ETF), valued at $5.23M, representing 1.46% of its reported portfolio and ranking #18.
Has WT Wealth Management been buying or selling PPH?
In the latest 13F filing (Q3 2026), WT Wealth Management reduced its position in PPH. The position peaked in Q2 2026 at 53.79K shares.
Which other funds hold PPH?
Other major institutional holders of PPH include J.Safra Asset Management Corp, Avalon Trust Co, ADAMSBROWN WEALTH CONSULTANTS LLC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.